It might be some time before Chinese biopharma companies have a presence in the US comparable to their European and Japanese counterparts, but with one Food and Drug Administration approval already and potentially two more on the way this year, they are undoubtably off to a strong start. Particularly important to the foothold they have gained is not only innovation, but other trends such as regulatory harmonization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?